Retatrutide Prescribed Online to North Carolina Residents
Medical Weight Loss Treatment in North Carolina
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving North Carolina
From the Research Triangle's innovation hubs to Charlotte's banking towers, the Blue Ridge Mountains to the Outer Banks, North Carolina offers incredible diversity. OmniRx Health matches that diversity with comprehensive telehealth services. Whether you're a tech worker in Raleigh, a retiree in Asheville, a student at Duke or UNC, or a military family near Fort Liberty, our platform delivers expert care tailored to Tar Heel lifestyles and needs.
Our providers are licensed by the North Carolina Medical Board to deliver comprehensive telehealth services statewide.
North Carolina pharmacies in Charlotte, Raleigh, the Triad, and throughout mountain and coastal communities ensure prescription access.
North Carolina has updated telehealth regulations to support virtual care delivery while maintaining patient safety standards.
North Carolina requires telehealth coverage parity for commercial insurers, making virtual care accessible and affordable.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in North Carolina?
- Yes, telehealth is legal in North Carolina. The state has regulations supporting virtual healthcare delivery, allowing licensed providers to offer comprehensive services.
- Can mountain community residents in NC use telehealth?
- Telehealth is essential for North Carolina's mountain communities, where specialist access may require long drives to urban centers. Our platform brings care to you.
- Does North Carolina insurance cover telehealth?
- Yes, North Carolina requires telehealth coverage parity for commercial insurers. Most plans cover virtual visits at rates comparable to in-person appointments.